Angiogenesis Inhibitor Drug-induced Benign Migratory Glossitis in a Patient of Juvenile-onset Recurrent Respiratory Papillomatosis under Maintenance Therapy
Namita Kalra, Rishi Tyagi, Amit Khatri, Khadeeja Kulood, Puja Sabherwal
Citation Information :
Kalra N, Tyagi R, Khatri A, Kulood K, Sabherwal P. Angiogenesis Inhibitor Drug-induced Benign Migratory Glossitis in a Patient of Juvenile-onset Recurrent Respiratory Papillomatosis under Maintenance Therapy. Int J Clin Pediatr Dent 2024; 17 (1):92-96.
Background: Benign migratory glossitis or geographic tongue is a chronic recurring inflammatory condition of the oral cavity. With its ephemeral characteristics, there has been reported literature showing its association with the administration of certain drugs including angiogenesis inhibitors. The antiangiogenic drugs act by selectively inhibiting the vascular endothelial growth factor (VEGF) signaling. It has been widely used as an adjunct and a maintenance agent for the treatment of various cancers.
Aims: This study aims to report probable characteristic oral mucosal changes in a patient with juvenile-onset recurrent respiratory papillomatosis (JORRP) under maintenance therapy with an antiangiogenesis drug.
Case description: The patient was presented with a burning sensation on having spicy food. This occurred after the completion of three cycles of bevacizumab infusion. It was associated with the appearance of migratory lesions over the tongue and evolved periods of remission and exacerbation. Clinical examination revealed lesions characteristic of the geographic tongue on the anterior two-thirds of the dorsal surface as well as the lateral surface of the tongue classified as type 2, according to Hume criteria. Oral examination revealed dental caries in relation to 52, 54, 62, 63, 74, and 85 teeth and grossly decayed 64. Topical lignocaine gel was instituted for symptomatic relief of the lesion. Full mouth rehabilitation with preventive and restorative therapeutic interventions was carried out.
Clinical significance and conclusion: The documented literature along with this report put forth a probable association of geographic tongue with the use of bevacizumab drugs which requires further detailed studies. These lesions generally require symptomatic treatment with assurance only. The etiology is poorly understood.
Campana F, Vigarios E, Fricain JC, et al. Geographic stomatitis with palate involvement. An Bras Dermatol 2019;94(4):449–451. DOI: 10.1590/abd1806-4841.20197774
Nandini DB, Bhavana SB, Deepak BS, et al. Paediatric geographic tongue: a case report, review and recent updates. J Clin Diagn Res. 2016;10(2):ZE05–ZE09. DOI: 10.7860/JCDR/2016/16452.7191
Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 2020;86:102017. DOI: 10.1016/j.ctrv.2020.102017
Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 2015;93:52–79. DOI: 10.1016/j.ejpb.2015.03.018
Lam SY, Lee CS, Sharma S, et al. Bevacizumab-induced dysphonia: a case report with brief review of literature. J Oncol Pharm Pract 2020;26(4):1032–1036. DOI: 10.1177/1078155219889388
Gavrilovic IT, Balagula Y, Rosen AC, et al. Characteristics of oral mucosal events related to bevacizumab treatment. Oncologist 2012;17(2):274–278. DOI: 10.1634/theoncologist.2011-0198
Di Lorenzo G, Porta C, Bellmunt J, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011;59(4):526–540. DOI: 10.1016/j.eururo.2011.01.002
Martinez-Garcia M, Roman-Sainz J, Silvestre-Torner N, et al. Bevacizumab-induced geographic tongue. Dermatol Pract Concept 2021;11(3):e2021043. DOI: 10.5826/dpc.1103a43
Sundar S, Burge F. Geographical tongue induced by axitinib. BMJ Case Rep 2015;2015:bcr2015211318. DOI: 10.1136/bcr-2015-211318
Ryan MA, Leu GR, Upchurch PA, et al. Systemic Bevacizumab (Avastin) for juvenile-onset recurrent respiratory papillomatosis: a systematic review. Laryngoscope 2021;131(5):1138–1146. DOI: 10.1002/lary.29084
Strong MS, Vaughan CW, Cooperband SR, et al. Recurrent respiratory papillomatosis: management with the CO2 laser. Ann Otol Rhinol Laryngol 1976;85(4 Pt 1):508–516. DOI: 10.1177/000348947608500412
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239–245. DOI: 10.1038/clpt.1981.154
Shibuya M. Vascular Endothelial Growth Factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2011;2(12):1097–1105. DOI: 10.1177/1947601911423031
Niu G, Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets 2010;11(8):1000–1017. DOI: 10.2174/138945010791591395
Johnson KE, Wilgus TA. Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. Adv Wound Care (New Rochelle) 2014;3(10):647–661. DOI: 10.1089/wound.2013.0517
Pammer J, Weninger W, Mildner M, et al. Vascular endothelial growth factor is constitutively expressed in normal human salivary glands and is secreted in the saliva of healthy individuals. J Pathol 1998;186(2):186–191. DOI: 10.1002/(SICI)1096-9896(1998100)186:2<186::AID-PATH148>3.0.CO;2-J
Cutright DE, Bauer H. Cell renewal in the oral mucosa and skin of the rat. I. Turnover time. Oral Surg Oral Med Oral Pathol 1967;23(2):249–259. DOI: 10.1016/0030-4220(67)90104-1
Wolff A, Joshi RK, Ekström J, et al. A guide to medications inducing salivary gland dysfunction, xerostomia, and subjective sialorrhea: a systematic review sponsored by the world workshop on oral medicine VI. Drugs R D 2017;17(1):1–28. DOI: 10.1007/s40268-016-0153-9
Hubiche T, Valenza B, Chevreau C, et al. Geographic tongue induced by angiogenesis inhibitors. Oncologist 2013;18(4):e16–e17. DOI: 10.1634/theoncologist.2012-0320
Fang P, Hu JH, Cheng ZG, et al. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One 2012;7(12):e49717. DOI: 10.1371/journal.pone.0049717
Maluf G, Caldas RJ, Fregnani ER, et al. A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants. Int J Implant Dent 2019;5(1):34. DOI: 10.1186/s40729-019-0188-0
Santos-Silva AR, Belizário Rosa GA, Castro Júnior Gd, et al. Osteonecrosis of the mandible associated with bevacizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115(6):e32–e36. DOI: 10.1016/j.oooo.2013.02.001
Takahashi H, Sato M, Tsukada K, et al. A retrospective study of oral adverse events with colorectal cancer chemotherapy using bevacizumab. Gan To Kagaku Ryoho 2011;38(6):959–962.